United Therapeutics (UTHR) Other financing activities (2009 - 2026)

United Therapeutics has disclosed Other financing activities across 18 years of filings, most recently posting $126.3 million for Q2 2026.

• In Q2 2026, Other financing activities rose 597.79% year-over-year to $126.3 million; the TTM figure through Jun 2026 stood at $333.8 million (up 259.31% YoY), while the FY2025 annual figure was $173.9 million, up 14.03% from the prior year.
• Other financing activities came in at $126.3 million for Q2 2026 at United Therapeutics, up from $68.3 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $126.3 million in Q2 2026 to a low of $4.3 million in Q1 2022.
• Average Other financing activities over 5 years is $39.3 million, with a median of $29.1 million recorded in 2024.
• The largest YoY upside for Other financing activities was 1327.91% in 2023 against a maximum downside of 86.85% in 2023.
• Over 5 years, Other financing activities stood at $55.5 million in 2022, then tumbled by 86.85% to $7.3 million in 2023, then soared by 252.05% to $25.7 million in 2024, then surged by 285.21% to $99.0 million in 2025, then gained by 27.58% to $126.3 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $126.3 million in Q2 2026, $68.3 million in Q1 2026, and $99.0 million in Q4 2025.